Safety Study of Nebivolol for COPD Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01939990|
Recruitment Status : Withdrawn (Funding was discontinued.)
First Posted : September 11, 2013
Last Update Posted : January 12, 2016
|Condition or disease||Intervention/treatment||Phase|
|High Blood Pressure||Drug: Placebo Drug: Nebivolol||Phase 2 Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Primary Purpose:||Health Services Research|
|Official Title:||Nebivolol in Chronic Obstructive Pulmonary Disease|
|Study Start Date :||January 2012|
|Actual Primary Completion Date :||March 2013|
|Actual Study Completion Date :||March 2013|
Active Comparator: Nebivolol
Group A will be given Nebivolol 5 to 10mg per day
5 to 10mg per day
Other Name: bystolic
Placebo Comparator: Placebo
Group B will be given Placebo.
The placebo looks like the study drug but it does not contain active ingredients.
Other Name: Placebo is a sugar pill.
- to assess blood pressure control [ Time Frame: baseline to 4 weeks ]blood pressure control will be assessed per collection of research data at protocol visits.
- to assess pulmonary function tests [ Time Frame: baseline to 4 weeks ]pulmonary function tests will be assessed at protocol visits
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01939990
|United States, Illinois|
|University of Chicago Medical Center|
|Chicago, Illinois, United States, 60637|
|Principal Investigator:||George Bakris, MD||University of Chicago|